"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab

Next Previous
Trial Profile

"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL_MIRO

    • Most Recent Events

    • 28 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top